<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39390732</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1386-6346</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Hepatology research : the official journal of the Japan Society of Hepatology</Title><ISOAbbreviation>Hepatol Res</ISOAbbreviation></Journal><ArticleTitle>Real-world trends in acute viral hepatitis in Japan: A nationwide questionnaire-based survey.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/hepr.14123</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">The actual incidence of acute viral hepatitis in Japan remains unclear. We aimed to investigate trends in the incidence of acute hepatitis B and C infections in Japan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A nationwide, multicenter, retrospective questionnaire-based survey was conducted. Participating hospitals received questionnaires through nationwide geographically distributed regional core centers certified as specialists in hepatitis treatment. The questionnaire included hospital size and the number of patients diagnosed with acute hepatitis B or C during each fiscal year (FY) from 2015 to 2022. The sex distribution in each FY was also documented. Comparisons were made before and during the COVID-19 era (2015-2019 vs. 2020-2022), and between populous and non-populous prefectures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Responses to the questionnaires were obtained from 127 institutions in 29 prefectures covering eight regions in Japan. A median of 127.0 patients with acute hepatitis B (interquartile range [IQR] 106.5-131.8 patients) were reported during each FY, and the incidence significantly decreased during the fiscal years 2020-2022 compared with the fiscal years 2015-2020 (median 96.0 [IQR 91.0-103.0] patients vs. 131.0 [IQR 128.0-134.0] patients; p = 0.03). A median of 10.0 (IQR, 7.8-13.5) patients were reported with acute hepatitis C during each FY. The proportions of men in acute hepatitis B and C were significantly higher in populous prefectures.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Populous prefectures had a higher proportion of men among viral hepatitis patients than non-populous prefectures. Estimating the high-risk populations in each area could provide insights to advance the elimination of viral hepatitis.</AbstractText><CopyrightInformation>© 2024 The Author(s). Hepatology Research published by John Wiley &amp; Sons Australia, Ltd on behalf of Japan Society of Hepatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Okushin</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9584-043X</Identifier><AffiliationInfo><Affiliation>Department of Infection Control and Prevention, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanto</LastName><ForeName>Tatsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hepatitis Information Center, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korenaga</LastName><ForeName>Masaaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hepatitis Information Center, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeuchi</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kishida</LastName><ForeName>Toshiyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kado</LastName><ForeName>Akira</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-4477-6858</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujishiro</LastName><ForeName>Mitsuhiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsutsumi</LastName><ForeName>Takeya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infection Control and Prevention, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takura</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Healthcare Economics and Health Policy, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Care Services Management, Nihon University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yotsuyanagi</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Kind Nationwide Institution Group for Hepatitis Treatment in Japan (Knight‐Japan)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Ministry of Health, Labor and Welfare</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Hepatol Res</MedlineTA><NlmUniqueID>9711801</NlmUniqueID><ISSNLinking>1386-6346</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute hepatitis B</Keyword><Keyword MajorTopicYN="N">acute hepatitis C</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">nationwide</Keyword><Keyword MajorTopicYN="N">sexually transmitted disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39390732</ArticleId><ArticleId IdType="doi">10.1111/hepr.14123</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Chang KC, Chang MH, Chen HL, Wu JF, Hsu HY, et al. Universal infant hepatitis B virus (HBV) vaccination for 35 Years: moving toward the eradication of HBV. J Infect Dis. 2022;225(3):431–435. https://doi.org/10.1093/infdis/jiab401</Citation></Reference><Reference><Citation>Buti M, Gane E, Seto WK, Chan HLY, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg‐negative chronic hepatitis B virus infection: a randomised, double‐blind, phase 3, non‐inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196–206. https://doi.org/10.1016/s2468‐1253(16)30107‐8</Citation></Reference><Reference><Citation>Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg‐positive chronic hepatitis B virus infection: a randomised, double‐blind, phase 3, non‐inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–195. https://doi.org/10.1016/s2468‐1253(16)30024‐3</Citation></Reference><Reference><Citation>Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898. https://doi.org/10.1056/nejmoa1402454</Citation></Reference><Reference><Citation>Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–2628. https://doi.org/10.1056/nejmoa1512614</Citation></Reference><Reference><Citation>Tanaka J, Akita T, Ko K, Miura Y, Satake M. Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view. Hepatol Res. 2019;49(9):990–1002. https://doi.org/10.1111/hepr.13417</Citation></Reference><Reference><Citation>National Institute of Infectious Diseases. IDWR surveillance data. Available from: https://www.niid.go.jp/niid/ja/ydata/11530‐report‐ja2021‐30.html. Accessed 8 July 2024.</Citation></Reference><Reference><Citation>National Institute of Infectious Diseases. IASR. 44 p33–p34. 2023. Available from: https://www.niid.go.jp/niid/ja/hepatitis‐a‐m/hepatitis‐a‐iasrtpc/11891‐517t.html. Accessed 8 July 2024.</Citation></Reference><Reference><Citation>National Institute of Infectious Diseases. IASR. 42 p1–p2. 2021. Available from: https://www.niid.go.jp/niid/ja/hepatitis‐c‐m/hepatitis‐c‐iasrtpc/10125‐491t.html. Accessed 8 July 2024.</Citation></Reference><Reference><Citation>Sako A, Yasunaga H, Horiguchi H, Hashimoto H, Masaki N, Matsuda S. Acute hepatitis B in Japan: incidence, clinical practices and health policy. Hepatol Res. 2011;41(1):39–45. https://doi.org/10.1111/j.1872‐034x.2010.00745.x</Citation></Reference><Reference><Citation>Ikeuchi K, Okushin K, Saito M, Adachi E, Tsutsumi T, Takura T, et al. Prevalence of HIV infection among non‐elderly individuals with hepatitis C in Japan: a population‐based cohort study using a health insurance claim data. BMC Infect Dis. 2022;22(1):167. https://doi.org/10.1186/s12879‐022‐07152‐5</Citation></Reference><Reference><Citation>National Center for Global Health and Medicine. The regional core centers. Available from: https://www.kanen.ncgm.go.jp/en/hosp.html. Accessed 7 July 2024.</Citation></Reference><Reference><Citation>Ito K, Yotsuyanagi H, Sugiyama M, Yatsuhashi H, Karino Y, Takikawa Y, et al. Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. J Gastroenterol Hepatol. 2016;31(1):180–189. https://doi.org/10.1111/jgh.13030</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>